Business Wire

Neustar Research Shows A DDoS Attack Can Cost An Organization On Average More Than $2.5 Million in Revenue

Share

Neustar, Inc. (NYSE: NSR), a trusted, neutral provider of real-time information services, today released the findings from its fourth annual Worldwide DDoS Attacks and Cyber Insights Research Report. The report documents the frequency and cost of attacks and what measures are being taken to counter these threats.

The Neustar May 2017 Worldwide DDoS Attacks and Cyber Insights Research Report, a 52-page global report, analyzes the responses of more than one thousand CISOs, CSO, CTOs security directors and managers. The report also includes, for the first time, Q1 attack data and trends captured from the Neustar DDoS Security Operations Center.

“Distributed Denial of Service (DDoS) attacks are the zeitgeist of today's Internet,” said Barrett Lyon, pioneer of the DDoS defense industry and Head of Research and Development at Neustar Security Solutions. “The question organizations must ask now is how they are prepared to manage these highly disruptive events. Are they prepared for the bad day where their customers call and ask why the website is down?”

Highlights from Neustar’s May 2017 Worldwide DDoS Attacks and Cyber Insights Research Report include:

DDoS Attack Trends

  • Volumetric attacks getting larger – 45 percent of DDoS attacks were more than 10 gigabits per second (Gbps); and, 15 percent of attacks were at least 50 Gbps, almost double the number reported last year.
  • Nowhere to hide – 849 out of 1,010 organizations were attacked with no particular industry spared, an increase of 15 percent since 2016. 727 – 86% of those attacked – were hit more than once.
  • Customers take on DDoS monitoring – 40 percent of respondents reported receiving attack alerts from customers, up from 29 percent in 2016.

Business Implication Trends

  • It’s a game of risk – 43 percent of organizations report average revenue loss of at least $250,000 per hour, with 51 percent taking at least three hours to detect an attack and 40 percent taking at least three hours to respond.
  • It’s a race against crime, rise in Ransomware – The instances of ransomware reported in concert with DDoS attacks increased 53 percent since 2016. 51 percent of attacks involved some sort of loss or theft with a 38 percent increase year over year in customer data, financial and intellectual property thefts.
  • What’s in place is not enough – 99 percent of organizations have some sort of DDoS protection in place, yet 90 percent of organizations are investing more than they did a year ago and 36 percent think they should be investing even more.

Neustar and Harris Interactive conducted global, independent research of 1,010 directors, managers, CISOs, CSOs, CTOs, and other c-suite executives to find out how DDoS attacks affect their organizations and what measures are in place to counter these threats. The respondents span many industries, including technology, financial services, retail, healthcare and energy. Nearly half of the organizations reported annual revenues from $500M to $1B per year.

Although Q4 is generally considered “DDoS season”, the Neustar Q1 attack data captured from the Neustar DDoS Security Operations Center highlights a number of key indicators that foreshadow this year will be another challenging one from a DDoS threat landscape perspective.

  • The year is off to a fast start – Q1 is generally considered “pre-season,” but Neustar is already seeing significant increases in average attack size and variety of attack vectors.
  • Emergence of new attack vectors – Attackers are constantly seeking new ways to turn legitimate infrastructure elements against their owners. Generic Routing Encapsulation (GRE) based flood attacks and Connectionless Lightweight Directory Access Protocol (CLDAP) reflection attacks are emerging as the new hot attack trends for 2017.
  • Attacks continue to get more complex – Multi-vector attacks have become the nearly universal experience for Neustar mitigation operations, demonstrating that attackers continue to launch more sophisticated attacks to penetrate organizations defenses.

Industry Leader Neustar Completes First Phase of Upgrade to 10 Tbps Global DDoS Mitigation Capacity

In conjunction with today’s release, Neustar announces it has tripled its global DDoS mitigation network capacity to 3 Tbps and will continue to significantly increase to 10 Tbps by early 2018. The construction, implementation and capacity of this new network is designed to stay ahead of the changing threat landscape and neutralize new and future volumetric DDoS attacks, as well as easily containing other types of DDoS attack vectors using proprietary DNS and IP intelligence data.

“At Experian, the experience of our end customers is of paramount importance for every interaction either with us directly, or via our global customer base. We have to have confidence that our website infrastructure can stand up to DDoS attacks and attacks on our DNS infrastructure, which is unfortunately a constant threat. Our relationship with Neustar is a significant component of our multi-faceted protection solution,” says Chris Matthews, Head of Operations, Experian Data Quality

“Innovation is in our DNA at Neustar, and we are pushing the limits of what was already considered a standard. We’re going well beyond any of our competitors or visions I had 20 years ago,” said Lyon. “With the completion of our new global constellation of scrubbing centers, we will have the largest, most distributed, and technically advanced DDoS defense network on the planet. We will not only be defending our large enterprise clients but also handling the overflow traffic many other providers will have during large attacks.”

Download Neustar’s Worldwide DDoS Attacks and Cyber Insights Research Report at ddosdefense.neustar.

Learn more about Neustar SiteProtect.

About Neustar
Every day, the world generates roughly 2.5 quadrillion bits of data. Neustar (NYSE: NSR) isolates certain elements and analyzes, simplifies and edits them to make precise and valuable decisions that drive results. As one of the few companies capable of knowing with certainty who is on the other end of every interaction, we’re trusted by the world’s great brands to make critical decisions some 20 billion times a day. We help marketers send timely and relevant messages to the right people. Because we can authoritatively tell a client exactly who is calling or connecting with them, we make critical realtime responses possible. And the same comprehensive information that enables our clients to direct and manage orders also stops attackers. We know when someone isn’t who they claim to be, which helps stop fraud and denial of service before they’re a problem. Because we’re also an experienced manager of some of the world’s most complex databases, we help clients control their online identity, registering and protecting their domain name, and routing traffic to the correct network address. By linking the most essential information with the people who depend on it, we provide more than 11,000 clients worldwide with decisions—not just data. More information is available at https://www.neustar.biz

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Neustar
Laura Cahill
Laura.cahill@axicom.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release

Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye